NASDAQ:GNCA Genocea Biosciences (GNCA) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsSEC FilingsTrendsBuy This Stock About Genocea Biosciences Stock (NASDAQ:GNCA) Get Genocea Biosciences alerts:Sign Up Key Stats Today's Range N/A50-Day Range N/A52-Week Range N/AVolume3,229 shsAverage Volume83,499 shsMarket Capitalization$6 thousandP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Genocea Biosciences, Inc. is a clinical-stage biotechnology company focused on the discovery and development of novel T cell-directed therapies and vaccines for oncology and infectious diseases. Headquartered in Cambridge, Massachusetts, Genocea aims to leverage the body’s natural immune response by identifying the precise antigens that drive protective T cell activity. The company’s proprietary ATLAS platform enables comprehensive mapping of antigen-specific CD4+ and CD8+ T cell responses. By screening patient-derived samples against a broad library of peptides, ATLAS identifies the targets most likely to elicit potent, disease-relevant immune responses. Genocea is applying this technology across multiple programs, including investigational cancer vaccines and infectious disease initiatives, and is pursuing strategic collaborations with pharmaceutical and biotechnology partners to advance its pipeline. Founded in 2011 as a spin-out from academic research, Genocea has built a multidisciplinary team of immunologists, molecular biologists and clinical development experts. While the company’s early work established proof of concept for its epitope identification approach, ongoing efforts are focused on translating ATLAS discoveries into off-the-shelf and personalized immunotherapies. Genocea serves a global market through its Cambridge laboratories and collaborative network, with the goal of accelerating next-generation treatments that harness T cell immunity.AI Generated. May Contain Errors. Read More Receive GNCA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Genocea Biosciences and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. GNCA Stock News HeadlinesGenocea Biosciences Inc.April 20, 2026 | barrons.comGenocea Biosciences Inc GNCAQJanuary 5, 2024 | morningstar.comMWhy this tiny stock may move before the SpaceX IPO dropsThe projected SpaceX and xAI S-1 filing hits the SEC on June 1st - and analyst Dylan Jovine says $1.75 trillion in stored capital will be looking for a home when it does. But the real opportunity isn't the IPO itself. Jovine has identified a small-cap supplier trading near $4 that sits directly in the path of xAI's Colossus infrastructure buildout - and a specific trigger in the S-1 could reprice it overnight.June 23 at 1:00 AM | Behind the Markets (Ad)GNCAQ Genocea Biosciences, Inc.January 26, 2023 | seekingalpha.com3 Health Care Stocks Under $10 to Trade for BreakoutsAugust 31, 2022 | thestreet.comGenocea Biosciences, Inc. (GNCA)August 9, 2022 | uk.finance.yahoo.comGRPN, GNCA and LAB among mid-day moversMay 27, 2022 | seekingalpha.comGenocea Biosciences to shut downMay 25, 2022 | finance.yahoo.comSee More Headlines GNCA Stock Analysis - Frequently Asked Questions How were Genocea Biosciences' earnings last quarter? Genocea Biosciences, Inc. (NASDAQ:GNCA) released its earnings results on Wednesday, October, 27th. The biotechnology company reported ($0.05) EPS for the quarter, topping analysts' consensus estimates of ($0.20) by $0.15. The biotechnology company had revenue of $1.64 million for the quarter. How do I buy shares of Genocea Biosciences? Shares of GNCA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Genocea Biosciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Genocea Biosciences investors own include Hawkins (HWKN), Chipotle Mexican Grill (CMG), BlackRock (BLK), Micron Technology (MU). Company Calendar Last Earnings10/27/2021Today6/23/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:GNCA CIK1457612 Webwww.genocea.com Phone(617) 876-8191Fax617-876-8192Employees70Year Founded2006Profitability EPS (Trailing Twelve Months)($0.61) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$33.20 million Net MarginsN/A Pretax Margin-1,946.15% Return on Equity-182.88% Return on Assets-62.76% Debt Debt-to-Equity Ratio0.24 Current Ratio1.35 Quick Ratio1.35 Sales & Book Value Annual Sales$1.91 million Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book Value$0.47 per share Price / BookN/AMiscellaneous Outstanding Shares58,730,000Free Float57,788,000Market Cap$6 thousand OptionableNot Optionable Beta1.61 Social Links The 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free Report This page (NASDAQ:GNCA) was last updated on 6/23/2026 by MarketBeat.com Staff. From Our PartnersTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredTrump Takes Emergency Action - Plus Elon Musk's New VentureElon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...Altimetry | SponsoredThe roadshow starts Monday. This stock isn't ready.The SpaceX roadshow kicks off June 8. Goldman Sachs, the lead underwriter, will present the full S-1 to the wo...Behind the Markets | SponsoredCODE RED: AI Meltdown Imminent?After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...Paradigm Press | SponsoredDo NOT Buy SpaceX – Do This InsteadSpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in coul...Stansberry Research | SponsoredTrump just signed itA recent policy development is drawing attention from income-focused investors. According to one analyst, c...Investors Alley | SponsoredSpaceX is chump change compared to Elon’s $20T ‘iPhone’Early Apple investors saw peak gains as high as 7,537% after the iPhone launched. Now, multiple insider source...StocksToTrade | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Genocea Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Genocea Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
